Management of brain metastases in ALK-positive non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 24, 2016, Pages 2814-2819

  Rusthoven, Chad G ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; B RAF KINASE; BRIGATINIB; CERITINIB; CORTICOSTEROID; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN RET; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METASTASIS; BRAIN; BRAIN DAMAGE; BRAIN METASTASIS; BRONCHOSCOPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DIAGNOSTIC IMAGING; DRUG PENETRATION; DRUG WITHDRAWAL; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG HILUS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PRIORITY JOURNAL; SMOKING; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TUMOR VOLUME; WHOLE BODY RADIATION; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SECONDARY;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84983438273     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.2410     Document Type: Article

References (52)

1. The National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology: Non small cell lung cancer. v4.2016. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#nscl
2. Shaw AT, Kim D-W, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
3. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
4. Weickhardt AJ, Scheier B, Burke JM, et al: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807-1814, 2012
5. Doebele RC, Pilling AB, Aisner DL, et al: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472-1482, 2012
6. Ou SH, Jänne PA, Bartlett CH, et al: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25:415-422, 2014
7. Costa DB, Kobayashi S, Pandya SS, et al: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445, 2011
8. Gainor JF, Ou SH, Logan J, et al: The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8:1570-1573, 2013
9. Toyokawa G, Seto T, Takenoyama M, et al: Insights into brain metastasis in patients with ALK1 lung cancer: Is the brain truly a sanctuary? Cancer Metastasis Rev 34:797-805, 2015
10. Guérin A, Sasane M, Zhang J, et al: Brain metastases in patients with ALK1 non-small cell lung cancer: Clinical symptoms, treatment patterns and economic burden. J Med Econ 18:312-322, 2015
11. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865-2872, 2004
12. Doebele RC, Lu X, Sumey C, et al: Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118:4502-4511, 2012
13. Johung KL, Yeh N, Desai NB, et al: Extended survival and prognostic factors for patients with ALKrearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123-129, 2016
14. Zhang I, Zaorsky NG, Palmer JD, et al: Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16:e510-e521, 2015
15. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
16. Mak KS, Gainor JF, Niemierko A, et al: Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol 17:296-302, 2015
17. Wang TJ, Saad S, Qureshi YH, et al: Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Neuro Oncol 17:1022-1028, 2015
18. 17a. Hayashi H, Okamoto I, Tanizaki J, et al: Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. J Clin Oncol 32:e122-e124, 2014
19. 17b. Narayanan V, Honce MJ, Mehrotra S, et al: Cystic brain metastases occurring in anaplastic lymphoma kinase gene rearranged non-small-cell lung cancer patients receiving crizotinib. Clin Lung Cancer 17:85-90, 2016
20. 17c. Saraceni C, Li PM, Gainor JF, et al: Cystic brain metastases in NSCLC harboring the EML4-ALK translocation after treatment with crizotinib. J Thorac Oncol 10:1116-1117, 2015
21. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
22. Solomon BJ, Cappuzzo F, Felip E, et al: Intracranial efficacy of crizotinib versus chemotherapy in patientswith advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014. J Clin Oncol [epub ahead of print on March 28, 2016]
23. Metro G, Lunardi G, Floridi P, et al: CSF concentration of crizotinib in two ALK-positive non-smallcell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10:e26-e27, 2015
24. Mima T, Toyonaga S, Mori K, et al: Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol Res 21:209-215, 1999
25. Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286, 2010
26. Grommes C, Oxnard GR, Kris MG, et al: "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364-1369, 2011
27. Gan GN, Weickhardt AJ, Scheier B, et al: Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinasepositive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88:892-898, 2014
28. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295:2483-2491, 2006
29. Brown PD, Asher AL, Ballman KV, et al: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol 33, 2015(suppl; abstr LBA4)
30. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
31. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
32. Mulvenna PM, Nankivell MG, Barton R, et al: Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). J Clin Oncol 33, 2015(suppl; abstr 8005)
33. Soffietti R, Kocher M, Abacioglu UM, et al: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 31:65-72, 2013
34. Bhatnagar AK, Flickinger JC, Kondziolka D, et al: Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64:898-903, 2006
35. Chang WS, Kim HY, Chang JW, et al: Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: Is stereotactic radiosurgery effective for multiple brain metastases? J Neurosurg 113:73-78, 2010(suppl)
36. Likhacheva A, Pinnix CC, Parikh NR, et al: Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85:656-661, 2013
37. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 15:387-395, 2014
38. Sahgal A, Aoyama H, Kocher M, et al: Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: Individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710-717, 2015
39. Gadgeel SM, Gandhi L, Riely GJ, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119-1128, 2014
40. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
41. Ou S-HI, Ahn JS, De Petris L, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 34:661-668, 2016
42. Gainor JF, Chi AS, Logan J, et al: Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol 11:256-260, 2016
43. Peled N, Zach L, Liran O, et al: Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol 8:e112-e113, 2013
44. Kim D-W, Mehra R, Tan DSW, et al: Activity and safety of ceritinib in patientswith ALK-rearranged nonsmallcell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol [epub ahead of print on March 10, 2016]
45. Camidge DR, Bazhenova L, Salgia R, et al: Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK1 non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015(suppl; abstr 8062)
46. Shi W, Dicker AP: CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol 34:107-109, 2016
47. Gainor JF, Sherman CA, Willoughby K, et al: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232-236, 2015
48. Kuribayashi H, Abe S, Kuse N, et al: Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma Int Cancer Conf J 5:69-72, 2016
49. Ou S-HI, Sommers KR, Azada MC, et al: Alectinib induces a durable (.15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 20:224-226, 2015
50. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998
51. Brennan C, Yang TJ, Hilden P, et al: A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88:130-136, 2014
52. Soltys S, Seiger K, Modlin L, et al: A phase I/II dose-escalation trial of 3-fraction stereotactic radiosurgery (SRS) for large resection cavities of brain metastases. Int J Radiat Oncol Biol Phys 93:S38, 2015